A dose escalation, safety, and tolerability study of denibulin [MN 029] administered every seven days in subjects with advanced metastatic solid tumors
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2013
At a glance
- Drugs Denibulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors MediciNova
- 06 Oct 2013 Status changed from recruiting to completed.
- 09 Nov 2007 Positive results have been reported.
- 31 Jan 2006 New trial record.